Accepted for/Published in: JMIR Formative Research
Date Submitted: Nov 19, 2021
Date Accepted: Feb 7, 2022
Date Submitted to PubMed: Feb 22, 2022
How vaccine ambivalence can lead people who inject drugs to decline COVID-19 vaccination, and ways this can be addressed: a Qualitative Study
ABSTRACT
Background:
People who inject drugs (PWID) are disproportionately impacted by SARS-CoV-2 and COVID-19, yet frequently do not accept vaccinations against SARS-CoV-2 when offered.
Objective:
To explore why PWID decline free vaccinations against SARS-CoV-2, and how barriers to vaccination can potentially be addressed.
Methods:
We conducted semi-structured qualitative interviews with 17 unvaccinated adult PWID during August and September 2021, at a New York City syringe service program.
Results:
Participants acknowledged they faced increased risk from SARS-CoV-2 due to their injection drug use, but feared long term substance use may have weakened their health, making them especially vulnerable to side effects. Fears of possible side effects, compounded by widespread medical mistrust and questions about the overall value of vaccination contributed to significant ambivalence among our sample.
Conclusions:
Community-developed messages are needed in outreach efforts to explain the importance of vaccination, including the far greater dangers of COVID-19 compared to possible unintended side effects. Messages delivered by trusted community members explaining their own decisions to vaccinate, and emphasizing vaccines’ ability to prevent inadvertently infecting loved ones, may help increase uptake. Community focused messaging strategies, like those used to increase HIV/HCV testing and overdose prevention among PWID, may prove similarly effective.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.